Poolbeg Pharma makes significant breakthrough in its AI programme with OneThree Biotech

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it has made a significant breakthrough in its Artificial Intelligence (‘AI’) Programme with partner OneThree Biotech, Inc. through the discovery of novel drug targets for the treatment of Respiratory Syncytial Virus (‘RSV’).

Following the completion of the build and optimisation of a tailored AI model in June 2022, the OneThree team, using its clinically validated AI platform, have identified novel drug targets using Poolbeg’s unique RSV human challenge trial data. The identification of these novel drug targets now allows the final stage of the programme to commence which will involve the identification of small molecule inhibitors to effectively treat RSV infections. The team are particularly excited as these include a range of targets for which there are known drugs with existing Phase I safety and tolerability data. Prioritisation of compounds with existing Phase I data aligns with Poolbeg’s capital light model as these compounds will have extensive nonclinical and clinical data allowing smooth transition to early human efficacy trials.

The final stage of the research plan will utilise OneThree’s proprietary ATLANTIS AI platform to identify the drugs that are most likely to be efficacious against the identified disease targets with clean safety profiles in RSV patients. Selection of drugs is traditionally a long and extensive process, however, by using an existing AI model this process can be completed in weeks. Results of this stage are expected before year end 2022.

Traditional drug design is focused on identifying a molecule that can bind with a specific target within a cell. Poolbeg’s approach, utilising OneThree Biotech’s advanced AI models, allows for the complex disease signature underlying each drug target to be considered during drug selection. This allows the complex outputs of this stage, which represent novel biological insights, to be advanced to the final stage which will match drugs to prioritised targets. By working from disease signatures like this, OneThree Biotech can utilise the full strength of its AI technology to pinpoint the drug molecules that can precisely and effectively reverse disease signatures and produce meaningful clinical benefits.

Neel S. Madhukar, PhD, CEO of OneThree Biotech said:

“This analysis is pioneering in RSV research, and we are pleased to have identified disease targets from which effective drug candidates can be explored. We are fortunate to have access to Poolbeg’s unique human challenge trial data because it was collected in a controlled and powered quarantine which increases the overall strength and predictive power you can get from it. Additionally, thanks to the combination of Poolbeg’s data and our ATLANTIS platform, we were able to reach this point in our project in only eight months – significantly faster than a traditional drug discovery project – and we’re excited to make meaningful progress in the treatment of infectious diseases, such as RSV.”

Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said:

“This is the first time that AI has been used to identify disease targets in RSV and I am delighted to have reached this significant milestone in the programme in such a short period of time. Having identified these novel disease targets, we can now commence the final stage of the programme to identify effective drug candidates to treat RSV. In keeping with our capital-light model, this AI enabled in silico R&D approach has significantly accelerated the discovery process by having the right partners and the right expertise to unleash the potential of our unique human challenge trial data. We greatly look forward to seeing the outputs of this programme later this year.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn

More articles like this

New results for severe influenza and inflammatory conditions

Poolbeg Pharma, an infectious disease-focused biopharmaceutical company, has announced data from the bacterial lipopolysaccharide (‘LPS’) human challenge trial for POLB 001, a viral strain agnostic, small molecule immunomodulator being developed to address the unmet medical need arising from

Poolbeg Pharma releases positive data from influenza trial

Poolbeg Pharma has released new data from a human challenge trial that shows its treatment has strong potential in dampening inflammation in blood and tissues in influenza and other viral infections. POLB 001 showed success in reducing multiple markers

Poolbeg Pharma granted patent by USPTO for POLB 001

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF),  a leading infectious disease focused biopharmaceutical company, has announced that further to its announcement on 4 October 2022, it has been granted a patent by the US Patent and Trademark Office (USPTO) for methods of treating hypercytokinaemia

Positive results from Poolbeg Pharma’s human challenge trial

Poolbeg Pharma – a company focused on developing infectious disease therapies – has announced data from its bacterial lipopolysaccharide (LPS) human challenge trial for POLB 001. The treatment is a viral strain agnostic, small molecule immunomodulator which is

SLAS2023: We have the building blocks, onto the building

In the time that has passed since SLAS2022 in Boston, USA, the drug discovery industry has had to deal with all manner of external obstacles, from the war in Ukraine, to how Brexit has changed the world’s relationship

The small drug firms set to benefit from RSV vaccines

Here’s an investment idea that starts with large blue-chip companies, but has significant trickle-down potential to at least three smaller, growth companies listed in the UK. Chances are RSV, or respiratory syncytial virus, which has symptoms similar to

Poolbeg Pharma Investment Case

Poolbeg Pharma (LON:POLB / OTCQB:POLBF) Investment Case with CEO Jeremy Skillington. Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company with a unique capital light model. The company is focus on targeting the significant global medical need to treat

AI continues to gain momentum in the biopharmaceutical industry in 2023

While the biopharmaceutical industry has been impacted and pressured by various factors such as the Covid-19 pandemic, inflation, the Ukraine-Russia war, ongoing supply chain issues, and a challenging economic environment, collaboration between pharma companies and emerging technologies providers

Elaine Sullivan on International Day of Women & Girls in Science

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Donegal man hopes to raise $1 billion in Nasdaq launch

A Donegal man hopes to raise one billion dollars when his latest venture launches on New York’s Nasdaq. Poolbeg Pharma is planning to list on the stock exchange as chairman Cathal Friel (58), from Creeslough, eyes another $1bn

The race to supercharge cancer-fighting T cells

CAR-T therapies capitalize on the activities of T cells, the immune system’s natural hunters that prowl through the body looking for things that don’t belong. Foreign cells, or those infected with a virus, express unusual proteins that serve

AI continues to gain momentum in the biopharmaceutical industry in 2023

While the biopharmaceutical industry has been impacted and pressured by various factors such as the Covid-19 pandemic, inflation, the Ukraine-Russia war, ongoing supply chain issues, and a challenging economic environment, collaboration between pharma companies and emerging technologies providers

No more posts to show